Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Differential [18F]FAPI-42 and [18F]FDG uptake patterns distinguish desmoid tumours from GISTs on PET/CT imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-025-07707-z
BACKGROUND: Intra-abdominal desmoid tumours (IADT) can closely mimic gastrointestinal stromal tumours (GISTs), particularly in recurrence and metastases. However, differentiating these two diseases using radiological methods remains challenging. This study aimed to investigate the value of [ 18F]FAPI-42 PET/CT in differentiating IADT and GISTs compared to [ 18F]FDG PET/CT. METHODS: This study retrospectively included a total of 24 patients (12 patients with IADT and 12 patients with recurrent/metastatic GISTs) who underwent two separate PET/CT scans using [ 18F]FAPI-42 and [ 18F]FDG, respectively. The differences in tumour SUV max on...
Chunhui Wu, Xiaoyan Wang, Xiaojie Lin, Andor W J M Glaudemans, Bart Cornelissen, Walter Noordzij, Xin Hu, Yu Zeng, Xiangsong Zhang, Xinhua Zhang
Positron emission tomography imaging of inflammation and infection in children: an update
Published in: Seminars in Nuclear Medicine
Access to document
10.1053/j.semnuclmed.2026.04.006
document
Positron emission tomography (PET) has been used in pediatric oncology since the modality gained traction 20 years ago but has been used more sparingly in infectious and inflammatory diseases due to the ionizing radiation involved. However, more recent PET/CT systems allowing for the reduction of radiation dose have resulted in markedly more referrals, for these indications, over the past decade. Pediatric patients present unique challenges due to age-dependent physiology, nonspecific symptoms, and comorbidities, complicating diagnosis and limiting the utility of conventional imaging. [¹⁸F]-Fluorodeoxyglucose ([ 18F]FDG) PET/CT offers sensitive...
André H Dias, Marie Ø Fosbøl, Oleksandra V Ivashchenko, Flemming L Andersen, Ole L Munk, Riemer H J A Slart, Andor W J M Glaudemans, Lars C Gormsen
Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-025-07711-3
document
Fibroblast activation protein-targeted radionuclide therapy (FAP-TRT) has emerged as a novel strategy for modulating the tumour microenvironment (TME) by selectively eradicating FAP-expressing cancer-associated fibroblasts (CAFs). Although preclinical studies have demonstrated promising results across various tumour models using diverse radiolabelled FAP inhibitors, clinical translation remains limited by modest efficacy, short tumour retention, and highly heterogeneousresponses. This review aims to provide an overview of recent advances in radiopharmaceutical design to enhance tumour targeting and prolong retention. Furthermore, we summarise early clinical findings and ongoing trials, while emphasising the potential translational...
Validation of a Deep-Learning Coregistration Framework for Long-Axial-Field-of-View PET/CT Using Low-Radiation-Exposure Protocols Across Various Tracers
Published in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Access to document
10.2967/jnumed.125.270420
document
The advent of long-axial-field-of-view (LAFOV) PET/CT systems has significantly improved whole-body imaging by providing higher sensitivity and extended torso coverage. However, PET/CT potential misalignment remains a challenge, potentially introducing artifacts and quantification errors. Moreover, PET protocols with reduced scanning duration and dose, as well as the use of ultra-low-dose CT (ULD-CT), are increasingly relevant in clinical practice and research. This study aimed to evaluate the robustness and generalizability of a deep-learning coregistration framework for PET/CT alignment using low-dose PET and ULD-CT across various tracers with a LAFOV system....
Zekai Li, Laura Providência, Philipp Mohr, Samaneh Mostafapour, Mostafa Roya, T Samara Martinez-Lucio, Joost F Somsen, Goudje L van Leeuwen, Giordana Salvi De Souza, Joyce van Sluis, Andor W J M Glaudemans, Rudi A J O Dierckx, Jean-Paul P M de Vries, Gert Luurtsema, Riemer H J A Slart, Adrienne H Brouwers, Paul Schleyer, Maurizio Conti, Adriaan A Lammertsma, Joshua SchaefferkoetterCharalampos Tsoumpas
PET imaging of polymyalgia rheumatica: update and future trends
Published in: Seminars in Nuclear Medicine
Access to document
10.1053/j.semnuclmed.2026.03.008
document
Polymyalgia rheumatica (PMR) is a common immune-mediated inflammatory disease affecting older adults over 50 years of age and is characterized by constitutional symptoms with disabling pain and stiffness. Diagnosis remains challenging as clinical features can overlap with other inflammatory musculoskeletal conditions. 18F-fluoro-2-deoxy-d-glucose ([ 18F]FDG-PET/CT) has emerged as a valuable imaging modality by enabling rapid assessment of the hallmarks of PMR: extracapsular and musculotendinous inflammation at characteristic sites localizing to the shoulders, hips, pelvis, spinous processes and knees. In addition, [ 18F]FDG-PET/CT has established its utility in identifying concurrent...
Bonnia Liu, Ellen Hendrikse, Kornelis S M van der Geest, Elisabeth Brouwer, Andor W J M Glaudemans, Riemer H J A Slart